Patents by Inventor Thomas A. Bell, III

Thomas A. Bell, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
    Publication number: 20200056176
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.
    Type: Application
    Filed: May 28, 2019
    Publication date: February 20, 2020
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Adam Mullick, Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie, Thomas A. Bell, III, Richard Lee
  • MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
    Publication number: 20170268004
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.
    Type: Application
    Filed: May 25, 2017
    Publication date: September 21, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Adam Mullick, Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie, Thomas A. Bell, III, Richard Lee
  • MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
    Publication number: 20160060625
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.
    Type: Application
    Filed: August 7, 2015
    Publication date: March 3, 2016
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Adam Mullick, Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie, Thomas A. Bell, III, Richard Lee
  • MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
    Publication number: 20140128453
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.
    Type: Application
    Filed: April 27, 2012
    Publication date: May 8, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Adam Mullick, Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie, Thomas A. Bell, III, Richard Lee
  • MODULATION OF CETP EXPRESSION
    Publication number: 20130053430
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a CETP mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or HDL activity and reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
    Type: Application
    Filed: April 7, 2011
    Publication date: February 28, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Thomas A. Bell, III, Rosanne M. Crooke, Mark J. Graham